1.
Reeves M, Khoury J, Alwell K, Moomaw C, Flaherty M, Woo D, et al. Distribution of
National Institutes of Health stroke scale in the Cincinnati/Northern Kentucky Stroke
Study. Stroke. 2013;44(11):3211-3.
2.
Kim BJ, Park JM, Kang K, Lee SJ, Ko Y, Kim JG, et al. Case characteristics, hyperacute
treatment, and outcome information from the clinical research center for stroke-fifth
division registry in South Korea. J Stroke. 2015;17(1):38-53.
3.
Messe SR, Khatri P, Reeves MJ, Smith EE, Saver JL, Bhatt DL, et al. Why are acute
ischemic stroke patients not receiving IV tPA? Results from a national registry. Neurology.
2016;87(15):1565-74.
4.
Khatri P, Conaway MR, Johnston KC. Ninety-day outcome rates of a prospective cohort
of consecutive patients with mild ischemic stroke. Stroke. 2012;43(2):560-2.
5.
Amarenco P, Lavallee PC, Labreuche J, Albers GW, Bornstein NM, Canhao P, et al. One-Year
Risk of Stroke after Transient Ischemic Attack or Minor Stroke. N Engl J Med. 2016;374(16):1533-42.
6.
Amarenco P, Lavallee PC, Monteiro Tavares L, Labreuche J, Albers GW, Abboud H, et
al. Five-Year Risk of Stroke after TIA or Minor Ischemic Stroke. N Engl J Med. 2018;378(23):2182-90.
7.
Khatri P, Tayama D, Cohen G, Lindley RI, Wardlaw JM, Yeatts SD, et al. Effect of Intravenous
Recombinant Tissue-Type Plasminogen Activator in Patients With Mild Stroke in the
Third International Stroke Trial-3: Post Hoc Analysis. Stroke. 2015;46(8):2325-7.
8.
You S, Saxena A, Wang X, Tan W, Han Q, Cao Y, et al. Efficacy and safety of intravenous
recombinant tissue plasminogen activator in mild ischaemic stroke: a meta-analysis.
Stroke Vasc Neurol. 2018;3(1):22-7.
9.
Lees KR, Emberson J, Blackwell L, Bluhmki E, Davis SM, Donnan GA, et al. Effects of
Alteplase for Acute Stroke on the Distribution of Functional Outcomes: A Pooled Analysis
of 9 Trials. Stroke. 2016;47(9):2373-9.
10.
Emberson J, Lees KR, Lyden P, Blackwell L, Albers G, Bluhmki E, et al. Effect of treatment
delay, age, and stroke severity on the effects of intravenous thrombolysis with alteplase
for acute ischaemic stroke: a meta-analysis of individual patient data from randomised
trials. The Lancet. 2014;384(9958):1929-35.
11.
Greisenegger S, Seyfang L, Kiechl S, Lang W, Ferrari J, Austrian Stroke Unit Registry
C. Thrombolysis in patients with mild stroke: results from the Austrian Stroke Unit
Registry. Stroke. 2014;45(3):765-9.
12.
Powers WJ, Rabinstein AA, Ackerson T, Adeoye OM, Bambakidis NC, Becker K, et al. 2018
Guidelines for the Early Management of Patients With Acute Ischemic Stroke: A Guideline
for Healthcare Professionals From the American Heart Association/American Stroke Association.
Stroke. 2018;49(3):e46-e110.
13.
Chen W, Pan Y, Zhao X, Liu L, Li H, Liao X, et al. Intravenous Thrombolysis in Chinese
Patients with Different Subtype of Mild Stroke: Thrombolysis in Patients with Mild
Stroke. Sci Rep. 2017;7(1):2299.
14.
Khatri P, Kleindorfer DO, Devlin T, Sawyer RN, Jr., Starr M, Mejilla J, et al. Effect
of Alteplase vs Aspirin on Functional Outcome for Patients With Acute Ischemic Stroke
and Minor Nondisabling Neurologic Deficits: The PRISMS Randomized Clinical Trial.
Jama. 2018;320(2):156-66.
15.
Rothwell PM, Giles MF, Flossmann E, Lovelock CE, Redgrave JNE, Warlow CP, et al. A
simple score (ABCD) to identify individuals at high early risk of stroke after transient
ischaemic attack. The Lancet. 2005;366(9479):29-36.
16.
Knoflach M, Lang W, Seyfang L, Fertl E, Oberndorfer S, Daniel G, et al. Predictive
value of ABCD2 and ABCD3-I scores in TIA and minor stroke in the stroke unit setting.
Neurology. 2016;87(9):861-9.
17.
Adams HP, Jr., Bendixen BH, Kappelle LJ, Biller J, Love BB, Gordon DL, et al. Classification
of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical
trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke. 1993;24(1):35-41.
18.
Tissue plasminogen activator for acute ischemic stroke. N Engl J Med. 1995;333(24):1581-7.
19.
Lee S-J, Hong JM, Lee SE, Kang DR, Ovbiagele B, Demchuk AM, et al. Association of
fibrinogen level with early neurological deterioration among acute ischemic stroke
patients with diabetes. BMC Neurol. 2017;17(1).
20.
de Los Rios la Rosa F, Khoury J, Kissela BM, Flaherty ML, Alwell K, Moomaw CJ, et
al. Eligibility for Intravenous Recombinant Tissue-Type Plasminogen Activator Within
a Population: The Effect of the European Cooperative Acute Stroke Study (ECASS) III
Trial. Stroke. 2012;43(6):1591-5.
21.
Romano JG, Smith EE, Liang L, Gardener H, Camp S, Shuey L, et al. Outcomes in mild
acute ischemic stroke treated with intravenous thrombolysis: a retrospective analysis
of the Get With the Guidelines-Stroke registry. JAMA Neurol. 2015;72(4):423-31.
22.
Choi JC, Jang MU, Kang K, Park JM, Ko Y, Lee SJ, et al. Comparative Effectiveness
of Standard Care With IV Thrombolysis Versus Without IV Thrombolysis for Mild Ischemic
Stroke. Journal of the American Heart Association. 2015;4(1).
23.
Whiteley WN, Slot KB, Fernandes P, Sandercock P, Wardlaw J. Risk factors for intracranial
hemorrhage in acute ischemic stroke patients treated with recombinant tissue plasminogen
activator: a systematic review and meta-analysis of 55 studies. Stroke. 2012;43(11):2904-9.
24.
Strbian D, Piironen K, Meretoja A, Sairanen T, Putaala J, Tiainen M, et al. Intravenous
thrombolysis for acute ischemic stroke patients presenting with mild symptoms. Int
J Stroke. 2013;8(5):293-9.
25.
Ng FC, Coote S, Frost T, Bladin C, Choi PM. CT perfusion predicts tissue injury in
TIA and minor stroke. J Neurol. 2017;264(4):802-3.
26.
Ng FC, Coote S, Frost T, Bladin C, Choi PM. Utility of Computed Tomographic Perfusion
in Thrombolysis for Minor Stroke. Stroke. 2016;47(7):1914-6.
27.
Yoshimura S, Lindley RI, Carcel C, Sato S, Delcourt C, Wang X, et al. NIHSS cut point
for predicting outcome in supra- vs infratentorial acute ischemic stroke. Neurology.
2018;91(18):e1695-e701.
28.
Merwick Á, Albers GW, Amarenco P, Arsava EM, Ay H, Calvet D, et al. Addition of brain
and carotid imaging to the ABCD2 score to identify patients at early risk of stroke
after transient ischaemic attack: a multicentre observational study. The Lancet Neurology.
2010;9(11):1060-9.
29.
Song B, Fang H, Zhao L, Gao Y, Tan S, Lu J, et al. Validation of the ABCD3-I score
to predict stroke risk after transient ischemic attack. Stroke. 2013;44(5):1244-8.
30.
Wang Y, Wang Y, Zhao X, Liu L, Wang D, Wang C, et al. Clopidogrel with aspirin in
acute minor stroke or transient ischemic attack. N Engl J Med. 2013;369(1):11-9.
31.
Johnston SC, Easton JD, Farrant M, Barsan W, Battenhouse H, Conwit R, et al. Platelet-oriented
inhibition in new TIA and minor ischemic stroke (POINT) trial: rationale and design.
Int J Stroke. 2013;8(6):479-83.